Holen Sie sich die Stockscreener-App
318.10
0.05%
0.15
Handel nachbörslich:
318.10
Schlusskurs vom Vortag:
$317.95
Offen:
$318.24
24-Stunden-Volumen:
146.60K
Relative Volume:
0.34
Marktkapitalisierung:
$12.51B
Einnahmen:
$1.45B
Nettoeinkommen (Verlust:
$171.05M
KGV:
73.20
EPS:
4.3459
Netto-Cashflow:
$212.73M
1W Leistung:
-0.15%
1M Leistung:
-0.39%
6M Leistung:
-1.35%
1J Leistung:
+30.44%
1-Tages-Spanne:
$317.35
$318.51
1-Wochen-Bereich:
$316.49
$320.03
52-Wochen-Spanne:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
318.10 | 12.51B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-11-18 | Eingeleitet | Wells Fargo | Underweight |
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Enterprise value to EBITDA forward of Penumbra, Inc. – NYSE:PEN - TradingView
Penumbra starts trial of clot removal device in stroke subgroup - MedTech Dive
What Is Driving Penumbra (NYSE:PEN) on the NYSE Composite? - Kalkine Media
Penumbra enrolls first patient in distal acute stroke thrombectomy study - MassDevice
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT - AOL.com
Penumbra initiates study on stroke treatment for distal occlusions - Investing.com
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke - BioSpace
Penumbra (PEN) Launches FORWARD Study to Assess Stroke Treatment Methods - GuruFocus
Penumbra initiates study on stroke treatment for distal occlusions By Investing.com - Investing.com Canada
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT - GlobeNewswire Inc.
Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Innovator with a 14.40% Potential Upside - DirectorsTalk Interviews
PENPenumbra Inc Volatility & Greeks - Finviz
Penumbra shareholders approve merger with Boston Scientific - Investing.com
Penumbra Inc. (PEN) Holds Steady Near Resistance Level as Trading Volume Remains ModerateDollar Neutral Pair - dars.gov.et
Price to earnings forward of Penumbra, Inc. – DUS:0P8 - TradingView
Penumbra Receives CE Mark for Reperfusion Catheters - dicardiology.com
Penumbra secures European CE mark for Red 72 Silver Label technologies - NeuroNews International
Penumbra Inc (PEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Penumbra, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh - TradingView
REAL Aspiration Catheter from Penumbra Inc.large-vessel stroke workhorse for interventional suite - AD HOC NEWS
PEN Forecast — Price Target — Prediction for 2027 - TradingView
Penumbra Update - TMX Newsfile
Price to book forward of Penumbra, Inc. – HAM:0P8 - TradingView
Enterprise value to EBITDA forward of Penumbra, Inc. – HAM:0P8 - TradingView
Penumbra, Inc. Actuals & Estimates (XETR:0P8) - TradingView
PEN Stock Price Prediction 2025-2026 | Penumbra Inc Forecast - 24/7 Wall St.
Price to sales forward of Penumbra, Inc. – HAM:0P8 - TradingView
Price to earnings forward of Penumbra, Inc. – HAM:0P8 - TradingView
0P8 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Penumbra, Inc. – NYSE:PEN - TradingView
Enterprise value to EBIT forward of Penumbra, Inc. – NYSE:PEN - TradingView
Form 8K Penumbra Inc For: 22 June By Investing.com - Investing.com South Africa
Penumbra, Inc. 8-K SEC Filing: Key Details, Business Address, NYSE Listing & Shareholder Vote Results - Minichart
Penumbra shareholders elect directors and approve executive pay at annual meeting - Investing.com Nigeria
Penumbra: Portfolio Expands With Approval To Treat Stroke; Acquisition by Boston on Track - Morningstar
Penumbra Expands Portfolio With Approval To Treat Stroke; Acquisition by Boston on Track - Morningstar
Penumbra (PEN) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary - Quartr
Penumbra StockAnalyst and earnings outlook as consensus settles - AD HOC NEWS
(PEN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Penumbra (NYSE:PEN) Medical Device Mid Caps Stay In Focus - Kalkine Media
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain? - TradingView
Why Penumbra Lightning Flash is drawing attention in stroke care - AD HOC NEWS
Penumbra wins CE mark for Thunderbolt clot removal tech - MedTech Dive
Penumbra Inc (PEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Penumbra Inc (PEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Penumbra (PEN) Proxy filing Summary - Quartr
Penumbra Inc (PEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Penumbra Inc (PEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Penumbra Inc (PEN) Institutional Confidence - TradingKey
Penumbra Inc (PEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Penumbra Inc (PEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):